{"id":32059,"date":"2025-04-18T18:24:05","date_gmt":"2025-04-18T10:24:05","guid":{"rendered":"https:\/\/flcube.com\/?p=32059"},"modified":"2025-04-18T18:24:06","modified_gmt":"2025-04-18T10:24:06","slug":"takedas-adzynma-beigenes-sonrotoclax-and-avistones-andatinib-set-for-priority-review-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32059","title":{"rendered":"Takeda&#8217;s Adzynma, BeiGene&#8217;s Sonrotoclax, and Avistone&#8217;s Andatinib Set for Priority Review in China"},"content":{"rendered":"\n<p>The website of China&#8217;s Center for Drug Evaluation (CDE) indicates that Takeda&#8217;s (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>) Adzynma (apadamtase alfa), BeiGene, Ltd.&#8217;s (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) sonrotoclax, and Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd&#8217;s andatinib are on course to obtain priority review statuses. This development highlights the potential of these therapies to address significant unmet medical needs.<\/p>\n\n\n\n<p><strong>Adzynma: Recombinant ADAMTS13 Protein<\/strong><br>Adzynma is a recombinant ADAMTS13 protein designed for on-demand or prophylactic enzyme replacement therapy (ERT) in children and adults with congenital thrombotic thrombocytopenic purpura (cTTP). Its priority review status reflects the urgent need for effective treatments for this rare and life-threatening condition.<\/p>\n\n\n\n<p><strong>Sonrotoclax: BCL2 Inhibitor<\/strong><br>Sonrotoclax, a BCL2 inhibitor, is intended for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received anti-CD20 and BTKi therapy. It is also indicated for adult patients with previously treated chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL). The priority review status underscores its potential to improve outcomes in these challenging hematological malignancies.<\/p>\n\n\n\n<p><strong>Andatinib: EGFR Inhibitor<\/strong><br>Andatinib is an epidermal growth factor receptor (EGFR) inhibitor being developed for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). It is specifically targeted at patients who have undergone platinum-based chemotherapy and\/or PD-1\/PD-L1 immunotherapy, or who have experienced disease progression or intolerance after treatment, and have been confirmed to have an EGFR exon 20 insertion mutation. This priority review status highlights its importance in the treatment landscape for advanced NSCLC with EGFR mutations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The website of China&#8217;s Center for Drug Evaluation (CDE) indicates that Takeda&#8217;s (TYO: 4502) Adzynma&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32060,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4010,185,16,847,3046,80,24,848,345,1141],"class_list":["post-32059","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-avistone-pharmaceuticals-biotechnology","tag-beigene","tag-cancer","tag-hkg-6160","tag-nasdaq-onc","tag-priority-reviews","tag-rare-orphan-disease-drugs","tag-sha-688235","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda&#039;s Adzynma, BeiGene&#039;s Sonrotoclax, and Avistone&#039;s Andatinib Set for Priority Review in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The website of China&#039;s Center for Drug Evaluation (CDE) indicates that Takeda&#039;s (TYO: 4502) Adzynma (apadamtase alfa), BeiGene, Ltd.&#039;s (NASDAQ: ONC, HKG: 6160, SHA: 688235) sonrotoclax, and Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd&#039;s andatinib are on course to obtain priority review statuses. This development highlights the potential of these therapies to address significant unmet medical needs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32059\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda&#039;s Adzynma, BeiGene&#039;s Sonrotoclax, and Avistone&#039;s Andatinib Set for Priority Review in China\" \/>\n<meta property=\"og:description\" content=\"The website of China&#039;s Center for Drug Evaluation (CDE) indicates that Takeda&#039;s (TYO: 4502) Adzynma (apadamtase alfa), BeiGene, Ltd.&#039;s (NASDAQ: ONC, HKG: 6160, SHA: 688235) sonrotoclax, and Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd&#039;s andatinib are on course to obtain priority review statuses. This development highlights the potential of these therapies to address significant unmet medical needs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32059\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-18T10:24:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T10:24:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1817.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda&#8217;s Adzynma, BeiGene&#8217;s Sonrotoclax, and Avistone&#8217;s Andatinib Set for Priority Review in China\",\"datePublished\":\"2025-04-18T10:24:05+00:00\",\"dateModified\":\"2025-04-18T10:24:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059\"},\"wordCount\":264,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1817.webp\",\"keywords\":[\"Avistone Pharmaceuticals Biotechnology\",\"BeiGene\",\"Cancer\",\"HKG: 6160\",\"NASDAQ: ONC\",\"Priority reviews\",\"Rare \\\/ orphan disease drugs\",\"SHA: 688235\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32059#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32059\",\"name\":\"Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1817.webp\",\"datePublished\":\"2025-04-18T10:24:05+00:00\",\"dateModified\":\"2025-04-18T10:24:06+00:00\",\"description\":\"The website of China's Center for Drug Evaluation (CDE) indicates that Takeda's (TYO: 4502) Adzynma (apadamtase alfa), BeiGene, Ltd.'s (NASDAQ: ONC, HKG: 6160, SHA: 688235) sonrotoclax, and Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd's andatinib are on course to obtain priority review statuses. This development highlights the potential of these therapies to address significant unmet medical needs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32059\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1817.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1817.webp\",\"width\":1080,\"height\":608,\"caption\":\"Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32059#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda&#8217;s Adzynma, BeiGene&#8217;s Sonrotoclax, and Avistone&#8217;s Andatinib Set for Priority Review in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China - Insight, China&#039;s Pharmaceutical Industry","description":"The website of China's Center for Drug Evaluation (CDE) indicates that Takeda's (TYO: 4502) Adzynma (apadamtase alfa), BeiGene, Ltd.'s (NASDAQ: ONC, HKG: 6160, SHA: 688235) sonrotoclax, and Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd's andatinib are on course to obtain priority review statuses. This development highlights the potential of these therapies to address significant unmet medical needs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32059","og_locale":"en_US","og_type":"article","og_title":"Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China","og_description":"The website of China's Center for Drug Evaluation (CDE) indicates that Takeda's (TYO: 4502) Adzynma (apadamtase alfa), BeiGene, Ltd.'s (NASDAQ: ONC, HKG: 6160, SHA: 688235) sonrotoclax, and Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd's andatinib are on course to obtain priority review statuses. This development highlights the potential of these therapies to address significant unmet medical needs.","og_url":"https:\/\/flcube.com\/?p=32059","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-18T10:24:05+00:00","article_modified_time":"2025-04-18T10:24:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1817.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32059#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32059"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda&#8217;s Adzynma, BeiGene&#8217;s Sonrotoclax, and Avistone&#8217;s Andatinib Set for Priority Review in China","datePublished":"2025-04-18T10:24:05+00:00","dateModified":"2025-04-18T10:24:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32059"},"wordCount":264,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32059#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1817.webp","keywords":["Avistone Pharmaceuticals Biotechnology","BeiGene","Cancer","HKG: 6160","NASDAQ: ONC","Priority reviews","Rare \/ orphan disease drugs","SHA: 688235","Takeda","TYO: 4502"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32059#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32059","url":"https:\/\/flcube.com\/?p=32059","name":"Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32059#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32059#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1817.webp","datePublished":"2025-04-18T10:24:05+00:00","dateModified":"2025-04-18T10:24:06+00:00","description":"The website of China's Center for Drug Evaluation (CDE) indicates that Takeda's (TYO: 4502) Adzynma (apadamtase alfa), BeiGene, Ltd.'s (NASDAQ: ONC, HKG: 6160, SHA: 688235) sonrotoclax, and Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd's andatinib are on course to obtain priority review statuses. This development highlights the potential of these therapies to address significant unmet medical needs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32059#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32059"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32059#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1817.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1817.webp","width":1080,"height":608,"caption":"Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32059#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda&#8217;s Adzynma, BeiGene&#8217;s Sonrotoclax, and Avistone&#8217;s Andatinib Set for Priority Review in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1817.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32059"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32059\/revisions"}],"predecessor-version":[{"id":32061,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32059\/revisions\/32061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32060"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}